Anemia

43 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Broader: Hematologic Diseases

Narrower: Anemia, Aplastic 5, Anemia, Refractory, with Excess of Blasts 12, Anemia, Sickle Cell 13, beta-Thalassemia 3, Hemoglobinuria, Paroxysmal 3, Vaso-Occlusive Crises 1

Treatments and conditions

Anemia
Treatment and conditionWhere it standsTrials
Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Benserazide Only Product for beta-thalassemiaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Famotidine + PANTOPRAZOLE for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BMS-986470 + Placebo for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
CREADY (Cognitive-Remediation of Executive and Adaptive Deficits in Youth) for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Crizanlizumab for anemia, sickle cellTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Cyclophosphamide for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Danicopan for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Echocardiography + Electrocardiogram (ECG) + DEFERIPRONE + Deferoxamine + Deferasirox for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
EDIT-301 for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Elritercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Exagamglogene autotemcel for anemia, sickle cellPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)5
Exagamglogene autotemcel for beta-thalassemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)2
Exerenibart for beta-thalassemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Busulfan + FLUDARABINE + Melphalan + Mycophenolate Mofetil Hydrochloride for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Granulocyte Colony-Stimulating Factor (G-CSF) + MGTA 456 Infusion + Total Body Irradiation (TBI) + Cyclophosphamide + FLUDARABINE + Mycophenolate Mofetil Hydrochloride + Tacrolimus for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
GVHD prophylaxis regimen + RIC regimen for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Hydroxycarbamide for anemia, sickle cellPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Iloprost for vaso-occlusive crisesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Iron sucrose for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Isatuximab for anemia, aplasticPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Luspatercept for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)3
Mitapivat for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Mobilized CD34-selected Peripheral Blood Stem Cell graft for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 1 Dose Level 1 + Phase 1 Dose Level 2 + Phase 1 Dose Level 3 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Maximum Tolerated Dose determined in Phase 1 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Placebo for Oral Azacitidine for anemiaPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Pozelimab + cemdisiran for hemoglobinuria, paroxysmalPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Proton Total Marrow Irradiation for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
reduced-dose conditioning regimen containing TBI in hematopoietic stem cell transplantation treating elderly patients with aplastic anemia for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Rivogenlecleucel + rimiducid for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Romiplostim for anemia, aplasticPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)2
Romiplostim for anemia, refractory, with excess of blastsPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Ruxoprubart for hemoglobinuria, paroxysmalTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation for anemia, sickle cellPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
thrombopoietin receptor agonist (TPO-RA) + Cyclosporine + ROMIPLOSTIM for anemia, aplasticTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Total-Body Irradiation + Umbilical Cord Blood Transplantation + Cyclophosphamide + THIOTEPA + DILANUBICEL + FLUDARABINE for anemia, refractory, with excess of blastsTrials ended early, as of 19 Nov 2026 (not yet checked by a person)1
Tranexamic acid for anemiaPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1
Unmanipulated Bone Marrow Graft with Cyclophosphamide + Cyclophosphamide for anemia, refractory, with excess of blastsPhase 3 trial, as of 19 Nov 2026 (not yet checked by a person)1

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.